Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib + Rituximab in Treatment-Naive Non-High-Risk MCL
NCT07199296Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jul 2025
- Primary completion
- Jul 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of orelabrutinib in mantle cell lymphoma (MCL), sponsored by Ruijin Hospital. Primary endpoint: Complete Response Rate. Started Jul 2025; status: recruiting.
02
Drugs
orelabrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT07199296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07199296.